Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Goldman Sachs Starts Atara Biotherapeutics (ATRA) at Neutral
November 10, 2014 7:20 AM ESTGoldman Sachs initiated coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Neutral rating and a price target of $30.00.
Analyst Navdeep Singh said, "Atara is an early-stage biotech developing (1) PINTA 745 for kidney dialysis patients who suffer from muscle wasting and (2) STM 434 for advanced ovarian... More
Jefferies Starts Atara Biotherapeutics (ATRA) at Buy
November 10, 2014 7:13 AM ESTJefferies initiates coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Buy rating and a price target of $35.00.
Analyst Ryan Martins states, "ATRA has a proven management team with extensive experience in licensing and developing products. We believe ATRA's two lead clinical products, PINTA 745 and STM 434,... More
